DK2819667T3 - Retinalderivater til anvendelse til forbedring af synsfunktionen - Google Patents

Retinalderivater til anvendelse til forbedring af synsfunktionen Download PDF

Info

Publication number: DK2819667T3
Authority: DK; Denmark
Prior art keywords: improve; vision function; retinal derivatives; retinal; derivatives
Prior art date: 2012-03-01

Application number

DK13760943.4T

Other languages

English (en)

Inventor

Suzanne Cadden

Original Assignee

Retinagenix Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-01

Filing date

2013-03-01

Publication date

2020-03-30

2013-03-01 Application filed by Retinagenix Therapeutics Inc filed Critical Retinagenix Therapeutics Inc

2020-03-30 Application granted granted Critical

2020-03-30 Publication of DK2819667T3 publication Critical patent/DK2819667T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Ophthalmology & Optometry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK13760943.4T 2012-03-01 2013-03-01 Retinalderivater til anvendelse til forbedring af synsfunktionen DK2819667T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261605729P	2012-03-01	2012-03-01
US201261642212P	2012-05-03	2012-05-03
US201261644360P	2012-05-08	2012-05-08
PCT/CA2013/050155 WO2013134867A1 (en)	2012-03-01	2013-03-01	Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

Publications (1)

Publication Number	Publication Date
DK2819667T3 true DK2819667T3 (da)	2020-03-30

Family

ID=49160185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13760943.4T DK2819667T3 (da)	2012-03-01	2013-03-01	Retinalderivater til anvendelse til forbedring af synsfunktionen

Country Status (17)

Country	Link
US (2)	US20160296478A1 (da)
EP (1)	EP2819667B8 (da)
JP (3)	JP6576636B2 (da)
KR (1)	KR102133608B1 (da)
CN (2)	CN109248163A (da)
AU (3)	AU2013232697B2 (da)
BR (1)	BR112014021602A2 (da)
CA (1)	CA2865935C (da)
DK (1)	DK2819667T3 (da)
ES (1)	ES2780357T3 (da)
HK (1)	HK1205469A1 (da)
IL (1)	IL234306B (da)
MX (1)	MX370928B (da)
NZ (1)	NZ629267A (da)
PT (1)	PT2819667T (da)
RU (1)	RU2635536C2 (da)
WO (1)	WO2013134867A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2622763C2 (ru)	2010-04-19	2017-06-19	Новелион Терапьютикс Инк.	Лечебная схема и способы лечения или уменьшения нарушений зрения, связанных с дефицитом эндогенных ретиноидов
CN109248163A (zh)	2012-03-01	2019-01-22	诺维利昂治疗股份有限公司	用于在与内源性维甲酸类缺乏相关的视觉障碍中改善视觉功能的治疗方案和方法
WO2015164419A1 (en) *	2014-04-22	2015-10-29	Acucela Inc.	Pupillometric assessment of retinal pharmacodynamics and responses therefrom
US20180170867A1 (en) *	2015-05-08	2018-06-21	University Of Debrecen	Stereoselective synthesis of 9-cis.13,14-dihydroretinoic acid and its ethyl esters
US12029715B2 (en) *	2015-05-08	2024-07-09	University Of Debrecen	Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof
AU2017359593B2 (en)	2016-11-17	2022-03-17	Universidade De Vigo	Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof
RU186184U1 (ru) *	2018-06-06	2019-01-11	Федеральное государственное бюджетное учреждение "33 Центральный научно-исследовательский испытательный институт" Министерства обороны Российской Федерации	Устройство для оценки углов обзора и поля зрения испытателей в противогазе
WO2024110625A1 (en)	2022-11-24	2024-05-30	Universität Bern	Cralbp based therapeutics for retinal disorders

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3196078A (en)	1962-01-30	1965-07-20	Ortho Pharma Corp	Process for combating retinits pigmentosa
US3517067A (en)	1964-02-11	1970-06-23	Eastman Kodak Co	Syntheses of quaternary phosphonium salts
DE2300107C2 (de)	1973-01-03	1982-03-11	Basf Ag, 6700 Ludwigshafen	Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
CH590222A5 (da)	1973-08-21	1977-07-29	Hoffmann La Roche
US4022913A (en)	1973-09-13	1977-05-10	Hoffmann-La Roche Inc.	High potency vitamin A compositions
DE2456959A1 (de)	1974-12-03	1976-06-16	Basf Ag	4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
CA1198859A (en)	1982-04-21	1986-01-07	Chester L. O'neal	Disposable toothbrush with cap
US4532133A (en)	1983-05-24	1985-07-30	Basf Wyandotte Corporation	Low temperature stable, emulsifiable vitamin A concentrates
CA1282326C (en)	1984-12-14	1991-04-02	Paul J. Jarosz	Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
JPS61275266A (ja)	1985-05-28	1986-12-05	Taisho Pharmaceut Co Ltd	レチノイド誘導体
CZ282548B6 (cs)	1992-01-22	1997-08-13	F. Hoffmann-La Roche Ag	Farmaceutický přípravek
US5310764A (en)	1992-05-08	1994-05-10	Steven Baranowitz	Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja)	1993-06-02	1994-12-13	Lion Corp	安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (en)	1994-04-04	1997-01-22	FREEMAN, William R.	Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru)	1994-06-29	1998-03-20	Красноярская государственная медицинская академия	Способ лечения близорукости
JPH08198746A (ja)	1995-01-18	1996-08-06	Lion Corp	可溶化点眼剤
US5837728A (en)	1995-01-27	1998-11-17	Molecular Design International	9-cis retinoic acid esters and amides and uses thereof
US5489611A (en)	1995-02-10	1996-02-06	Warner-Lambert Company	Method for lowering plasma levels of lipoprotein (a)
US5620970A (en)	1995-06-05	1997-04-15	Alcon Laboratories, Inc.	Topical ophthalmic carbonic anhydrase inhibitor formulations
EP0839029A1 (en)	1995-07-20	1998-05-06	PHARMACIA & UPJOHN COMPANY	Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
US5716627A (en)	1996-04-25	1998-02-10	Elizabeth Arden Co., Division Of Conopco, Inc.	Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en)	1997-08-23	1999-04-14	Werner Bollag	Treatment of cell-mediated immune diseases
ZA989513B (en)	1997-10-21	1999-04-21	Alcon Lab Inc	Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6391924B1 (en)	1997-12-10	2002-05-21	Hampar Karageozian	Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en)	1998-07-16	2003-04-22	Gentrix Llc	Compositions and methods of treating abnormal cell proliferation
US6267985B1 (en)	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
US6372463B1 (en)	1999-05-06	2002-04-16	The President & Fellows Of Harvard College	Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en)	1999-08-06	2001-10-09	Alcon Universal Ltd.	Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en)	2000-04-18	2002-03-07	Godkin James D.	Use of retinol in assisted-reproduction protocols
US6696069B2 (en)	2000-06-30	2004-02-24	Unilever Home & Personal Care Usa, Division Of Conopco, Inc.	Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US20040077604A1 (en)	2001-12-19	2004-04-22	Lenard Lichtenberger	Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
EP1261623B1 (en)	2001-01-11	2009-11-04	Chebigen Inc.	New retinol derivatives, the method of preparations and the uses thereof
EP1381276A4 (en)	2001-04-13	2005-02-02	Univ Pennsylvania	METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
ITMI20012366A1 (it)	2001-11-09	2003-05-09	Farmatron Ltd	Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
EP1450791A1 (en)	2001-11-30	2004-09-01	Kinetek Pharmaceuticals, Inc.	Hydrazonopyrazole derivatives and their use as therapeutics
EP1476147A4 (en)	2002-01-18	2005-03-09	Tatton Technologies Llc	METHODS OF TREATING VIEW DISORDERS
US20030215413A1 (en)	2002-03-22	2003-11-20	L'oreal	Compositions containing stabilized retinoid
US20040097587A1 (en)	2002-03-27	2004-05-20	Arbiser Jack L	Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
EP1536819A4 (en)	2002-03-29	2007-10-17	Maxim Pharm Inc	USING THE PRODUCTION OF REACTIVE OXYGEN METABOLITES (ROM) AND RELEASE INHIBITORS TO TREAT AND PREVENT INTRAOCULAR DAMAGE
JP3854524B2 (ja)	2002-04-01	2006-12-06	ピアス株式会社	油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法
EP1367493A1 (en)	2002-05-30	2003-12-03	STMicroelectronics Limited	Prefetch buffer
EP1527774A1 (en)	2003-11-03	2005-05-04	Basilea Pharmaceutica AG	New formulation for retinoid-containing soft gelatin capsules
US20060281821A1 (en)	2003-03-14	2006-12-14	Krzysztof Palczewski	Retinoid replacements and opsin agonists and methods for the use thereof
EP1510133A1 (en)	2003-09-01	2005-03-02	Belovo S.A., Egg Science & Technology	Balanced oil composition
ES2574004T3 (es)	2003-09-04	2016-06-14	The Uab Research Foundation	Procedimiento y aparato para la detección del deterioro en la adaptación a la oscuridad
US7706863B2 (en)	2004-01-21	2010-04-27	University Of Washington	Methods for assessing a physiological state of a mammalian retina
BRPI0507807A (pt)	2004-02-17	2007-07-31	Harvard College	gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular
WO2005084129A2 (en) *	2004-03-04	2005-09-15	Htl High-Tech Lipids Ltd.	Structured triglycerides and emulsions comprising same
CN1964706A (zh)	2004-03-17	2007-05-16	拉斯·M·拉森	通过抑制视觉周期预防视网膜病
EP2397132B1 (en)	2004-06-18	2017-07-26	University of Washington	Retinal derivatives and methods for the use thereof for the treatment of visual disorders
CA2569691C (en)	2004-06-23	2010-08-17	Sirion Therapeutics, Inc.	Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US20060240098A1 (en)	2004-07-14	2006-10-26	Aphios Corporation	Formulations for hyperforin-enriched hypericum fractions
EP1778207A2 (en)	2004-08-18	2007-05-02	Sytera Inc.	Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) *	2004-09-30	2006-04-13	The Regents Of The University Of California	Local administration of retinoids to treat deficiencies in dark adaptation
US20060177392A1 (en)	2005-02-10	2006-08-10	William Walden	Oil-based composition for acne
AU2006311818B9 (en)	2005-11-07	2013-05-16	Murty Pharmaceuticals, Inc	Improved delivery of tetrahydrocannabinol
US8202541B2 (en)	2006-02-07	2012-06-19	U.S. Nutraceuticals, LLC	Dietary supplement composition for blood lipid health
EP2069390A4 (en)	2006-07-27	2009-12-30	Univ Florida	OPSIN STABILIZING COMPOUNDS AND METHODS OF USE
PT2125697T (pt)	2007-01-15	2016-10-18	Yu Chongxi	Pró-fármacos solúveis em água positivamente carregados de retinóides e compostos tipo retinóide com taxas de penetração na pele muito altas
PT2187880E (pt)	2007-09-12	2014-03-25	Univ Columbia	Composições e métodos para o tratamento da degenerescência macular
CN101969938A (zh)	2008-02-11	2011-02-09	华盛顿大学	治疗和预防年龄相关视网膜功能障碍的方法
AU2009352678B2 (en)	2009-09-15	2015-05-21	Eluminex Biosciences (Suzhou) Limited	Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
FR2955459B1 (fr) *	2010-01-28	2013-11-22	Polaris	Composition huileuse riche en monoglycerides de dha
RU2622763C2 (ru) *	2010-04-19	2017-06-19	Новелион Терапьютикс Инк.	Лечебная схема и способы лечения или уменьшения нарушений зрения, связанных с дефицитом эндогенных ретиноидов
CN109248163A (zh)	2012-03-01	2019-01-22	诺维利昂治疗股份有限公司	用于在与内源性维甲酸类缺乏相关的视觉障碍中改善视觉功能的治疗方案和方法
US20150038582A1 (en)	2012-03-01	2015-02-05	Qlt Inc.	Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

2013
- 2013-03-01 CN CN201811054761.XA patent/CN109248163A/zh active Pending
- 2013-03-01 AU AU2013232697A patent/AU2013232697B2/en active Active
- 2013-03-01 EP EP13760943.4A patent/EP2819667B8/en active Active
- 2013-03-01 RU RU2014139666A patent/RU2635536C2/ru active
- 2013-03-01 BR BR112014021602A patent/BR112014021602A2/pt not_active Application Discontinuation
- 2013-03-01 CN CN201380022484.3A patent/CN104470511A/zh active Pending
- 2013-03-01 WO PCT/CA2013/050155 patent/WO2013134867A1/en active Application Filing
- 2013-03-01 MX MX2014010457A patent/MX370928B/es active IP Right Grant
- 2013-03-01 DK DK13760943.4T patent/DK2819667T3/da active
- 2013-03-01 KR KR1020147027749A patent/KR102133608B1/ko active IP Right Grant
- 2013-03-01 PT PT137609434T patent/PT2819667T/pt unknown
- 2013-03-01 NZ NZ629267A patent/NZ629267A/en not_active IP Right Cessation
- 2013-03-01 ES ES13760943T patent/ES2780357T3/es active Active
- 2013-03-01 CA CA2865935A patent/CA2865935C/en active Active
- 2013-03-01 JP JP2014559050A patent/JP6576636B2/ja active Active
2014
- 2014-08-26 IL IL234306A patent/IL234306B/en unknown
2015
- 2015-06-29 HK HK15106135.6A patent/HK1205469A1/xx not_active IP Right Cessation
2016
- 2016-04-11 US US15/096,048 patent/US20160296478A1/en not_active Abandoned
2017
- 2017-08-15 JP JP2017156807A patent/JP2017197588A/ja active Pending
2018
- 2018-01-18 AU AU2018200415A patent/AU2018200415B2/en not_active Expired - Fee Related
- 2018-06-11 US US16/005,155 patent/US10828267B2/en active Active
2019
- 2019-12-20 AU AU2019283995A patent/AU2019283995B2/en not_active Ceased
2020
- 2020-02-10 JP JP2020020391A patent/JP2020073597A/ja active Pending

Also Published As

Publication number	Publication date
MX2014010457A (es)	2015-04-08
AU2018200415B2 (en)	2019-09-26
EP2819667A1 (en)	2015-01-07
JP2020073597A (ja)	2020-05-14
CN104470511A (zh)	2015-03-25
JP2015508783A (ja)	2015-03-23
CA2865935C (en)	2021-12-14
KR20150000881A (ko)	2015-01-05
RU2014139666A (ru)	2016-04-20
US20190054039A1 (en)	2019-02-21
PT2819667T (pt)	2020-03-31
MX370928B (es)	2020-01-08
EP2819667A4 (en)	2015-08-05
WO2013134867A1 (en)	2013-09-19
ES2780357T3 (es)	2020-08-25
NZ629267A (en)	2016-11-25
US20160296478A1 (en)	2016-10-13
JP6576636B2 (ja)	2019-09-18
JP2017197588A (ja)	2017-11-02
CN109248163A (zh)	2019-01-22
IL234306B (en)	2022-02-01
AU2019283995A1 (en)	2020-01-23
BR112014021602A2 (pt)	2021-06-08
EP2819667B8 (en)	2020-03-04
KR102133608B1 (ko)	2020-07-13
EP2819667B1 (en)	2019-12-25
AU2013232697B2 (en)	2017-10-19
AU2013232697A1 (en)	2014-09-18
RU2635536C2 (ru)	2017-11-13
US10828267B2 (en)	2020-11-10
HK1205469A1 (en)	2015-12-18
AU2019283995B2 (en)	2021-11-11
AU2018200415A1 (en)	2018-02-08
CA2865935A1 (en)	2013-09-19

Publication	Publication Date	Title
CY2022027I1 (el)	2023-01-05	Παραγωγα βενζιμιδαζολο-προλινης
BR112015006198A2 (pt)	2017-07-04	conjunto de cadeira
CO7071126A2 (es)	2014-09-30	Derivados de piridona
BR302013002886S1 (pt)	2014-12-16	Configuração aplicada à cafeteira
BR302013002882S1 (pt)	2014-12-16	Configuração aplicada à cafeteira
BR112015003160A2 (pt)	2017-07-04	corantes de azaindolina - cianina substituídos por hidroxamato e bioconjugados dos mesmos
DK3263564T3 (da)	2020-09-07	Aza-aryl-1h-pyrazol-1-yl-benzen-sulfonamider som ccr(9)- antagonister
BR302013002883S1 (pt)	2014-12-16	Configuração aplicada à cafeteira
DK2846827T3 (da)	2019-05-13	Biofilmdesintegration med plyss2-lysin
CO7020919A2 (es)	2014-08-11	Derivados de tetrahidro-quinazolinona
DK2819667T3 (da)	2020-03-30	Retinalderivater til anvendelse til forbedring af synsfunktionen
FI20135047A (fi)	2014-05-14	Katseenohjausjärjestely
BR302013002885S1 (pt)	2014-12-16	Configuração aplicada à cafeteira
EP3040085A4 (en)	2017-04-19	Ophthalmic solution
FR2990774B1 (fr)	2018-09-28	Lentille ophtalmique
BR302012005880S1 (pt)	2014-06-03	Configuração aplicada em prótese
ES1078038Y (es)	2013-02-11	Aposito ocular
FR2990868B1 (fr)	2015-10-02	Autoinjecteur
FR2990869B1 (fr)	2015-09-04	Autoinjecteur
FR2990866B1 (fr)	2015-04-24	Autoinjecteur
FR2990865B1 (fr)	2015-04-24	Autoinjecteur
FR2994990B1 (fr)	2014-08-29	Volet de desenfumage
ES1081332Y (es)	2013-08-30	Protesis ocular
FR2999912B1 (fr)	2015-02-13	Composition concentree en dihydroxyyacetone
FR2990864B1 (fr)	2015-05-15	Autoinjecteur